---
title: "NEPG: The holding subsidiary has obtained approval for drug clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/260252068.md"
description: "NEPG announced that its holding subsidiary Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration. The drug name is DCTY0801 injection, and the indication is for EGFRvIII positive recurrent or progressive high-grade glioma. The approval of this clinical trial is an important milestone in the research and development process of this product, which will accelerate the progress of the company's research products and enhance the company's core competitiveness in the field of cancer treatment"
datetime: "2025-10-08T08:34:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260252068.md)
  - [en](https://longbridge.com/en/news/260252068.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260252068.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/260252068.md) | [繁體中文](https://longbridge.com/zh-HK/news/260252068.md)


# NEPG: The holding subsidiary has obtained approval for drug clinical trials

NEPG announced that its holding subsidiary Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The drug name is DCTY0801 injection, and the indication is for EGFRvIII positive recurrent or progressive high-grade glioma. The approval of this clinical trial is an important milestone in the research and development process of this product, which will accelerate the progress of the company's research products and enhance the company's core competitiveness in the field of cancer treatment

### Related Stocks

- [NEPG (000597.CN)](https://longbridge.com/en/quote/000597.CN.md)

## Related News & Research

- [Hengrui Pharmaceuticals Gets Nod to Trial SHR-9803 for Injection](https://longbridge.com/en/news/278830096.md)
- [AtaiBeckley: Lead Candidate Could Be Game-Changer For TRD Patients, Say Analysts](https://longbridge.com/en/news/278569850.md)
- [Xenon Pharmaceuticals Shares Surge on Positive Study Data for Azetukalner](https://longbridge.com/en/news/278422121.md)
- [GLP-1 Feud Ends: NOVO, HIMS Join Forces (Again) To Sell Obesity Drugs](https://longbridge.com/en/news/278234512.md)
- [05:59 ETEQT Foundation opens applications for science grants to overcome the blood-brain barrier and transform CNS drug delivery](https://longbridge.com/en/news/278530812.md)